Journal
JOURNAL OF CHILD PSYCHOLOGY AND PSYCHIATRY
Volume 62, Issue 6, Pages 701-703Publisher
WILEY
DOI: 10.1111/jcpp.13374
Keywords
-
Categories
Funding
- Therapix Biosciences
- Neurocrine Biosciences
- Janssen Pharmacueticals
- Biohaven Pharmaceuticals
- Emalex Biosciences
Ask authors/readers for more resources
This commentary highlights the scarcity of evidence for treating ADHD symptoms in the context of autism compared to other subpopulations such as tic disorders and intellectual disability, despite the extensive evidence base for treating ADHD in general. It discusses the dilemma clinicians face in relying on limited evidence for treating ADHD in specific subpopulations or deriving conclusions from the broader body of evidence on ADHD treatment. The commentary also explores potential avenues for future research to address this clinical problem.
In this issue, Rodrigues et al. (2020) present a systematic review with meta-analyses that reports the efficacy of five treatments for children with attention-deficit hyperactivity disorder symptoms in the context of autism spectrum disorder - (a) methylphenidate; (b) atomoxetine; (c) guanfacine; (d) aripiprazole; and (e) risperidone. In this commentary, we highlight the contrast between the scarce evidence base of treatment for ADHD in the context of autism and other subpopulations, such as tic disorders and intellectual disability, and the extensive evidence base of treatment for ADHD in general. The commentary weighs about the conundrum clinicians face of whether to rely on the limited evidence base of treatment for ADHD in subpopulation, or to derive conclusions from the larger body of evidence of treatment for ADHD in general. The commentary also discusses potential avenues for future research to address this clinical problem.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available